Clinical Trials
Everolimus does not improve overall survival of advanced liver cancer
July 25, 2014Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo, according to a study.
Resistant sarcomas slowed by new therapeutic combination
July 18, 2014A new therapeutic combination to combat resistant sarcomas has shown promise in a trial.
US Food and Drug Administration fast-tracks novel leukemia therapy
July 09, 2014An experimental immunotherapy agent was placed on the US Food and Drug Administration's fast track to market approval after overwhelmingly positive results were seen in patients with leukemia. In early trials, 89% of patients who received the personalized immunotherapy known as CTL019 saw their cancers disappear.
Surgical Biopsy Safe for Some Patients With Late-Stage Lung Cancer
July 08, 2014Surgical biopsy is safe for certain late-stage lung cancer patients and could improve their chances of getting treated with newer types of drugs that target cancer-related genetic mutations.
Direct injection treatment of pancreatic cancer shows encouraging results
July 03, 2014Results of a phase I clinical trial of a vaccine therapy for pancreatic cancer indicate the treatment is well tolerated; in addition, it suggests that the vaccine stabilizes the disease for a period of time.
Study demonstrates improved diagnosis and outcomes with LDCT
June 30, 2014A study using a 5-year LDCT screening protocol showed good adherence and patient survival outcomes in persons at high risk of developing lung cancer.
Developing an innovative online cancer information center
June 17, 2014An increasingly complex environment for cancer care and research highlights the need to streamline access to cancer information, especially clinical trials.
Phase 1 trials begin for first-in-class anticancer drug
June 16, 2014Clinical trials have begun for PFK-158, a small-molecule therapeutic candidate that inactivates a novel cancer metabolism target never before examined in human clinical trials.
Community Cancer Centers Program Participation Increases Rural Clinical Trial Enrollment
May 31, 2014Expanding the National Cancer Institute (NCI) Community Cancer Centers Program within a rural community can increase the number of patients enrolled in clinical trials
Shared Decision-making Ups Clinical Trial Participation, But Few Still Enroll
May 31, 2014Fewer than 5% of adults with cancer enroll in clinical trials, despite such enrollment being critical to evaluate new therapies.
Experimental treatment shows early promise for advanced neuroblastoma in children
May 23, 2014Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody.
Immunotherapy: A New Hope for NSCLC [Video]
May 21, 2014Created by the Society for Immunotherapy of Cancer (SITC), this video follows a sample patient's journey from the diagnosis of NSCLC through the process of learning about cancer immunology.
Risk-assessment approach outlined for biomarker-driven clinical trials
May 15, 2014A practical risk-management approach for effectively integrating biomarkers into cancer clinical trials has been outlined by a working group.
New experimental drug may be game-changer for acute myeloid leukemia
May 07, 2014Clinical trials for a new experimental drug, CPX-351, to treat acute myeloid leukemia are very promising, according to researchers.
Experts weigh in on managing elderly patients with NSCLC
May 06, 2014Approximately half of all patients with a diagnosis of non-small cell lung cancer are age 70 years or older, yet elderly patients are not well represented in clinical trials.
Intervention fidelity essential for clinical trials
May 03, 2014ANAHEIM, CALIFORNIA—Intervention fidelity is an essential element of randomized, clinical trials. To illustrate this point, one researcher described how intervention fidelity was incorporated into her clinical trial evaluating self-administration of acupressure for persistent cancer-related fatigue in breast cancer.
PD-L1 protein levels predict response to immunotherapy in lung cancer patients
April 25, 2014Among patients with non-small cell lung cancer treated with the investigational immune checkpoint inhibitor MK-3475, those whose tumors had high levels of the protein PD-L1 had significantly better outcomes.
Investigational drug benefits subgroup of patients with head and neck cancer
April 25, 2014Patients with recurrent or metastatic squamous cell carcinoma of the head and neck may benefit from treatment with the investigational drug dacomitinib.
First-in-class metabolism drug shown to be clinically active against advanced blood cancers
April 25, 2014AG-221, a novel inhibitor of isocitrate dehydrogenase 2-mutant metabolic enzyme, showed early promise in patients with advanced and refractory blood cancers harboring IDH2 mutations.
New drug shows promise in early studies for metastatic breast cancer
April 24, 2014The new oral drug LY2835219, an inhibitor of cyclin-dependent kinases 4 and 6, showed early promise as monotherapy for patients with metastatic breast cancer.
Early promise against melanoma from new antibody-drug conjugate
April 24, 2014The investigational drug DEDN6525A, a new antibody-drug conjugate, was safe, tolerable, and showed hints of activity against three forms of melanoma: cutaneous, mucosal, and ocular.
Subset of patients with breast cancer patients will most likely benefit from neratinib
April 23, 2014The I-SPY 2 trial identified a neo-adjuvant regimen containing the investigational drug neratinib and standard chemotherapy to be beneficial for HR-negative, HER2-positive primary (nonmetastatic) breast cancer patients.
New immunotherapy promising for advanced melanoma
April 22, 2014A new type of immunotherapy that directs patients' immune responses toward tumor cell killing, IMCgp100, showed efficacy in some patients with advanced melanoma.
Epigenetic therapy clinically active against several blood cancers
April 22, 2014Patients with a variety of hematologic cancers benefited from treatment with OTX015, a member of a new class of investigational epigenetic therapies that block the activity of bromodomain and extraterminal (BET)-bromodomain proteins.
Clinical trial success enhanced by biomarker- and receptor-targeted therapies in NSCLC
March 03, 2014Although the cumulative success rate for new agents for advanced NSCLC is lower than the industry-estimated rate, clinical trial success has been substantially increased by biomarker- and receptor-targeted therapies.
Assessing HRQOL is valuable in small-cell lung cancer trials
February 18, 2014Health-related quality of life assessment in randomized clinical trials in small cell lung cancer provides added information in studies where the treatment arms do not differ in terms of efficacy.
Clinical trial data on metformin for cancer are showing conflicting results
January 30, 2014The diabetes drug metformin is undergoing investigation as a potential treatment for different cancers in numerous clinical trials, but results vary.
Endoxifen promising as treatment for ER-positive breast cancer
January 06, 2014A phase 1 trial of endoxifen, an active metabolite of the cancer drug tamoxifen, indicates that the experimental drug is safe and provides early evidence for antitumor activity.
Innovative clinical trial design is a new paradigm in breast cancer research
January 02, 2014The first investigator results from an unprecedented nationwide effort to test promising new breast cancer drugs before the tumor is removed were presented during the 2013 San Antonio Breast Cancer Symposium.
Drug induces morphologic, molecular, and clinical remissions in myelofibrosis
December 25, 2013Imetelstat, a novel telomerase-inhibiting drug, has been found to induce morphologic, molecular, and clinical remissions in some patients with myelofibrosis, according to a new study. The results were presented at the 2013 ASH Annual Meeting, in New Orleans.
Sign Up for Free e-newsletters
ONA Articles
- Vasectomy may increase risk of aggressive prostate cancer
- Noninvasive advanced image analysis may improve care for lung cancer patients
- Colorectal cancer survival associated with higher vitamin D levels
- Protein inhibition opens door for pancreatic cancer treatment
- New blood test predicts risk of nonhereditary breast cancer
- Vasectomy may increase risk of aggressive prostate cancer
- The best cream for coffee may be the growing evidence of its cancer-preventive properties
- CRF relief: Exercise still trumps pharmaceutical interventions
- Diarrhea management in patients with rectal cancer
- New blood test predicts risk of nonhereditary breast cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |